Drug discovery in academia: the third way?

被引:45
作者
Frearson, Julie [1 ]
Wyatt, Paul [1 ]
机构
[1] Univ Dundee, Coll Life Sci, Div Biol Chem & Drug Discovery, Drug Discovery Unit, Dundee DD1 5EH, Scotland
基金
英国惠康基金;
关键词
academia; drug discovery; neglected disease; novel targets; RESEARCH-AND-DEVELOPMENT; OPEN INNOVATION; INDUSTRY;
D O I
10.1517/17460441.2010.506508
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
As the pharmaceutical industry continues to re-strategise and focus on low-risk, relatively short-term gains for the sake of survival, we need to re-invigorate the early stages of drug discovery and rebalance efforts towards novel modes of action therapeutics and neglected genetic and tropical diseases. Academic drug discovery is one model which offers the promise of new approaches and an alternative organisational culture for drug discovery as it attempts to apply academic innovation and thought processes to the challenge of discovering drugs in addressing real unmet need.
引用
收藏
页码:909 / 919
页数:11
相关论文
共 33 条
  • [1] A Wellcome experiment in seeding drug discovery
    不详
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (03) : 178 - 180
  • [2] [Anonymous], NIH ROADM MED RES
  • [3] Pharmaceutical sciences in 2020
    Crommelin, Daan
    Stolk, Pieter
    Besancon, Luc
    Shah, Vinod
    Midha, Kamal
    Leufkens, Hubert
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (02) : 99 - 100
  • [4] Drug discovery in jeopardy
    Cuatrecasas, Pedro
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (11) : 2837 - 2842
  • [5] Highlights in the Discovery of Antiviral Drugs: A Personal Retrospective
    De Clercq, Erik
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (04) : 1438 - 1450
  • [6] Frantz S, 2004, NAT REV DRUG DISCOV, V3, P541, DOI 10.1038/nrd1462
  • [7] N-myristoyltransferase inhibitors as new leads to treat sleeping sickness
    Frearson, Julie A.
    Brand, Stephen
    McElroy, Stuart P.
    Cleghorn, Laura A. T.
    Smid, Ondrej
    Stojanovski, Laste
    Price, Helen P.
    Guther, M. Lucia S.
    Torrie, Leah S.
    Robinson, David A.
    Hallyburton, Irene
    Mpamhanga, Chidochangu P.
    Brannigan, James A.
    Wilkinson, Anthony J.
    Hodgkinson, Michael
    Hui, Raymond
    Qiu, Wei
    Raimi, Olawale G.
    van Aalten, Daan M. F.
    Brenk, Ruth
    Gilbert, Ian H.
    Read, Kevin D.
    Fairlamb, Alan H.
    Ferguson, Michael A. J.
    Smith, Deborah F.
    Wyatt, Paul G.
    [J]. NATURE, 2010, 464 (7289) : 728 - U100
  • [8] HTS and hit finding in academia - from chemical genomics to drug discovery
    Frearson, Julie A.
    Collie, Iain T.
    [J]. DRUG DISCOVERY TODAY, 2009, 14 (23-24) : 1150 - 1158
  • [9] The Need for Precompetitive Integrative Bionetwork Disease Model Building
    Friend, S. H.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (05) : 536 - 539
  • [10] Thousands of chemical starting points for antimalarial lead identification
    Gamo, Francisco-Javier
    Sanz, Laura M.
    Vidal, Jaume
    de Cozar, Cristina
    Alvarez, Emilio
    Lavandera, Jose-Luis
    Vanderwall, Dana E.
    Green, Darren V. S.
    Kumar, Vinod
    Hasan, Samiul
    Brown, James R.
    Peishoff, Catherine E.
    Cardon, Lon R.
    Garcia-Bustos, Jose F.
    [J]. NATURE, 2010, 465 (7296) : 305 - U56